Stifel Maintains Buy on Zentalis Pharma, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has maintained a 'Buy' rating on Zentalis Pharma (NASDAQ:ZNTL), but lowered the price target from $44 to $36.
November 07, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Zentalis Pharma's price target has been lowered from $44 to $36 by Stifel, though the 'Buy' rating is maintained.
The news directly pertains to Zentalis Pharma (ZNTL). While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the short-term value of the stock. However, the maintained 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100